Lytix Biopharma ASA · OSL:LYTIX
Lytix Biopharma ASA — Investor Presentation (August 2013)
11 slides from Lytix Biopharma ASA's investor presentation, August 2013
Slide 1: LTX-109 – improving nature's own defense mechanisms
…improving nature’s own defense mechanisms LTX-109 August 2013
Slide 2: Lytix Biopharma scientific background
2 Lytix Biopharma scientific background T=5 minutes LTX-109 (infection) LTX-315 (cancer) Lactoferrin Lactoferricin The lactoferrin protein is found in milk and is known to have direct anti-microbial activity and cancer immune modulatory effects Structure-activity-relationship studies have result
Slide 3: Highly efficient peptides
3 Highly efficient peptides Ultra rapid membrane disruption Time: 0 min 5 min 10 min 20 min Host defence peptides form the cornerstone of the body’s protection against a broad spectrum of harmful micro-organisms Some host defence peptides kill micro-organisms by direct disruption of the cell mem
Slide 4: Significant commercial potential for LTX-109
4 Significant commercial potential for LTX-109 Global sales of topical antibacterials estimated to USD Bacterial resistance to antibiotics is a global and 982m in 20101 (primarily Bactroban and Fucidin) increasing problem Main product in market, Mupirocin, is used for skin Incidence of MRSA
Slide 5: LTX-109 is a well-documented drug candidate
5 LTX-109 is a well-documented drug candidate Fast acting, bactericidal antimicrobial drug Broad spectrum of activity Low propensity for resistance development Effective against multi-drug resistant bacteria Effective against biofilms
Slide 6: LTX-109 kills MRSA better than Gold Standard drugs
6 In-vivo animal studies: LTX-109 kills MRSA better than Gold Standard drugs Untreated Placebo 1% Altabax 2% Fusidic /Altargo Acid 1% Lytixar 2% Lytixar Murine skin infection model (tape-stripping, ATCC 33591) Read-out is bacterial growth +9 hours after the first of 3 doses
Slide 7: Project status LTX-109
7 Project status LTX-109 Phase I in healthy volunteers completed Phase I/IIa pilot study in Gram+ skin infections completed Phase I/IIa pilot study nasal decolonisation completed Focus in 2013 and 2014 Phase II PoC in impetigo Active dialog with potential partners
Slide 8: Impetigo – «milk blotch» in children
8 Impetigo – «milk blotch» in children Impetigo – Staphylococcus aureus and Streptococcus pyogenes – Pediatric disease – Incidence in 2-4 years old children – ~3 % UK – 12-25% in warmer humid climates Medical need – Increasing resistance to excisiting antibiotics (Fucidin and Bactroban) – Conven
Slide 9: Nasal decolonisation
9 Nasal decolonisation Medical need – Staphylococcus aureus are prevalent colonisers and the most common cause of hospital infections – MRSA (methicillin-resistant S. aureus) has become endemic in health care institutions worldwide, with up to 70% of invasive S. aureus infections having resistance
Slide 10: LTX-109 development milestones
10 LTX-109 development milestones Phase II Proof of Concept study in impetigo is ongoing. Results expected first half of 2014 Discussions with potential partners in the area of dermatology and topical infections are ongoing Effective killing of bacteria in the nose in a Phase I/IIa study. Resu
Slide 11: Lytix Biopharma AS - www.lytixbiopharma.com
Lytix Biopharma AS - www.lytixbiopharma.com
Lytix Biopharma — Investor Presentation (August 2013) on 6ix